Results 171 to 180 of about 51,875 (217)
Some of the next articles are maybe not open access.
International Journal of Dermatology, 1993
Rifampicin (Rp) is a semisynthetic derivative of Rifamycin B, an antimicrobial agent produced by Streptomyces mediterranei. Rp is a broad spectrum antimicrobial and inhibits the growth of most Gram-positive bacteria, as well as many Gram-negative microorganisms, such as Escherichia coli, Pseudomonas, indole-positive and indole-negative Proteus, and ...
N K, Tsankov, J A, Kamarashev
openaire +2 more sources
Rifampicin (Rp) is a semisynthetic derivative of Rifamycin B, an antimicrobial agent produced by Streptomyces mediterranei. Rp is a broad spectrum antimicrobial and inhibits the growth of most Gram-positive bacteria, as well as many Gram-negative microorganisms, such as Escherichia coli, Pseudomonas, indole-positive and indole-negative Proteus, and ...
N K, Tsankov, J A, Kamarashev
openaire +2 more sources
Pediatrics In Review, 1996
Rifampin is a semisynthetic derivative of rifamycin B that is active against a wide range of microorganisms and bactericidal for extracellular as well as intracellular pathogens. Most gram-positive and many gram-negative bacteria, as well as mycobactenia, are inhibited by nifampin.
openaire +2 more sources
Rifampin is a semisynthetic derivative of rifamycin B that is active against a wide range of microorganisms and bactericidal for extracellular as well as intracellular pathogens. Most gram-positive and many gram-negative bacteria, as well as mycobactenia, are inhibited by nifampin.
openaire +2 more sources
JAMA: The Journal of the American Medical Association, 1972
To the Editor.— Rifampin is an effective antituberculous drug recently approved by the Food and Drug Administration for general use. Users are warned that Rifampin has been shown to produce liver dysfunction. There have been fatalities associated with jaundice in patients with liver disease or receiving rifampin concomitantly with other hepatotoxic ...
openaire +2 more sources
To the Editor.— Rifampin is an effective antituberculous drug recently approved by the Food and Drug Administration for general use. Users are warned that Rifampin has been shown to produce liver dysfunction. There have been fatalities associated with jaundice in patients with liver disease or receiving rifampin concomitantly with other hepatotoxic ...
openaire +2 more sources
Annals of internal medicine, 1976
In 1971, rifampin was approved for treatment of pulmonary tuberculosis and asymptomatic carriers of Neisseria meningitidis. At present, the approved indications remain the same. However, rifampin in conjunction with at least one other antituberculous drug may be of great value in therapy of extrapulmonary tuberculosis and infections due to other ...
Gian G. Gallo, Pietro Radaelli
openaire +3 more sources
In 1971, rifampin was approved for treatment of pulmonary tuberculosis and asymptomatic carriers of Neisseria meningitidis. At present, the approved indications remain the same. However, rifampin in conjunction with at least one other antituberculous drug may be of great value in therapy of extrapulmonary tuberculosis and infections due to other ...
Gian G. Gallo, Pietro Radaelli
openaire +3 more sources
TO RIFAMPIN OR NOT TO RIFAMPIN?!
Journal of the American College of Cardiology, 2022Faysal Alhasan +2 more
openaire +1 more source
Clinical Infectious Diseases, 1983
Rifampin has proved to be a valuable antibiotic with relatively few major adverse effects. Its toxicity is predominantly hepatic and immunoallergic in character. While hepatic toxicity is dose related and has been observed mainly in patients with underlying liver disease, the immunoallergic effects are usually associated with intermittent or prolonged ...
J, Grosset, S, Leventis
openaire +2 more sources
Rifampin has proved to be a valuable antibiotic with relatively few major adverse effects. Its toxicity is predominantly hepatic and immunoallergic in character. While hepatic toxicity is dose related and has been observed mainly in patients with underlying liver disease, the immunoallergic effects are usually associated with intermittent or prolonged ...
J, Grosset, S, Leventis
openaire +2 more sources
Archives of Internal Medicine, 1984
Rifampin, an antituberculosis agent, is usually administered for nine to 12 months with other antituberculosis drugs or drugs from other classes. A potential for drug interactions often exists because this drug is a potent inducer of drug metabolism. Rifampin causes a proliferation of the smooth endoplasmic reticulum and an increase in the cytochrome P-
A M, Baciewicz, T H, Self
openaire +2 more sources
Rifampin, an antituberculosis agent, is usually administered for nine to 12 months with other antituberculosis drugs or drugs from other classes. A potential for drug interactions often exists because this drug is a potent inducer of drug metabolism. Rifampin causes a proliferation of the smooth endoplasmic reticulum and an increase in the cytochrome P-
A M, Baciewicz, T H, Self
openaire +2 more sources
Verapamil-Rifampin Interaction
Drug Intelligence & Clinical Pharmacy, 1985A case of verapamil-rifampin interaction is presented in a patient receiving verapamil for supraventricular tachycardia (SVT) and rifampin for pulmonary tuberculosis. The patient experienced recurrent symptomatic SVT, despite receiving verapamil 480 mg po q6h. Serum verapamil concentrations were determined to be extremely low.
openaire +2 more sources